Kuros Biosciences AG · ISIN: CH0325814116 · EQS - Company News

Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft

Kuros Biosciences AG / Key word(s): Study results/Scientific publication Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft 25.06.2024 / 07:00 CET/CEST Schlieren (Zurich), Switzerland, June 25, 2024 – Kuros Biosciences, a leader in next generation bone healing technologies, today announced the publication of a peer-reviewed manuscript that details the clinical data of its MAXA Level 1...

SIX:KURN Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Kuros Biosciences AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (0)
Short Selling (DE) (0)
Short Selling (UK) (0)
25 June 2024 07:00AM
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft
CH0325814116
Kuros Biosciences AG / Key word(s): Study results/Scientific publication Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft 25.06.2024 / 07:00 CET/CEST Schlieren (Zurich), Switzerland, June 25, 2024 – Kuros Biosciences, a leader in next ...
Kuros Biosciences AG
About the publication
24 April 2024 07:00AM
Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales
CH0325814116
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023; this corresponds to a sequential increase of 21.9% or CHF 2.5 million over Q4 2023  Total Kuros Medical Devices segment sales accelerated to CHF 13.9 million in Q1 2024 from CHF 5.6 million in Q1 2023 Kuros Medical Devices segm...
Kuros Biosciences AG
About the publication
13 March 2024 07:00AM
Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023
CH0325814116
Financial highlights Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million in 2022. Total medical device sales accelerated by 153% from CHF 13.3 million in 2022 to CHF 33.6 million in 2023  The Medical Devices segment achieved a positive EBITDA of CHF 6.8 million driven by MagnetOs Cash and cash equivalen...
Kuros Biosciences AG
About the publication
08 March 2024 07:00AM
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update
CH0325814116
Kuros Biosciences AG / Key word(s): Annual Results Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update 08.03.2024 / 07:00 CET/CEST -    Company to host conference call and webcast on March 13, 2024, at 3pm CET/10am US EST Schlieren (Zurich), Switzerland, March 8, 2024 – Kuros Bioscienc...
Kuros Biosciences AG
About the publication
01 February 2024 07:00AM
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
CH0325814116
Kuros Biosciences AG / Key word(s): Conference Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference 01.02.2024 / 07:00 CET/CEST Schlieren (Zurich), Switzerland, February 1, 2024 – Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it will present...
Kuros Biosciences AG
About the publication
31 January 2024 07:00AM
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
CH0325814116
Kuros Biosciences AG / Key word(s): Regulatory Admission/Market Launch Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand 31.01.2024 / 07:00 CET/CEST MagnetOs™ Granules becomes the third product in the MagnetOs...
Kuros Biosciences AG
About the publication
04 January 2024 07:00AM
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA
CH0325814116
Kuros Biosciences AG / Key word(s): Study results/Preliminary Results Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA 04.01.2024 / 07:00 CET/CEST New level 1 data from the MAXA ...
Kuros Biosciences AG
About the publication
27 December 2023 07:00AM
STRUCTURE and MAXA
CH0325814116
In the MAXA trial, standalone MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in a difficult-to-treat real life patient population (20% smokers). In the STRUCTURE trial, MagnetOs mixed with autograft showed posterolateral fusion rates comparable to autograft fusion rates in the less challenging interbody space I...
Kuros Biosciences AG
About the publication
28 November 2023 06:00PM
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
CH0325814116
Kuros Biosciences AG / Key word(s): Regulatory Approval Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages 28.11.2023 / 18:00 CET/CEST MagnetOs is the first open fibrillar collagen matrix bone graft substitute to receive clearance to market for interbody use MagnetOs can now be used...
Kuros Biosciences AG
About the publication
12 October 2023 07:00AM
Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management
CH0325814116
Direct MagnetOs sales grew to CHF 20.4 million in the first nine months of 2023, climbing from CHF 8.1 million in the same period in 2022.  Total medical device sales accelerated from CHF 9.0 million to CHF 21.3 million The Medical Devices segment achieved a positive EBITDA of CHF 3.8 million driven by MagnetOs Cash & cash equivalents amounte...
Kuros Biosciences AG
About the publication
09 August 2023 07:00AM
Kuros Biosciences Reports Results for First Half 2023
CH0325814116
Financial Highlights Direct MagnetOs sales increased by 148% from CHF 4.9 million to CHF 12.2 million, total revenue from medical devices rose from CHF 5.7 million to CHF 12.9 million  Medical Devices segment achieved a positive EBITDA of CHF 2.2 million driven by MagnetOs Cash & cash equivalents amounted to CHF 16.9 million, funds available...
Kuros Biosciences AG
About the publication
13 July 2023 07:29PM
Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial
CH0325814116
Kuros Biosciences AG / Key word(s): Study results Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial 13.07.2023 / 19:29 CET/CEST First investigational trial of drug-biologic bone graft for spinal fusion 50 patients have been enrolled in the Phase 2 trial Potential to addres...
Kuros Biosciences AG
About the publication
13 July 2023 07:29PM
Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial
CH0325814116
Kuros Biosciences AG / Key word(s): Study results Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial 13.07.2023 / 19:29 CET/CEST First investigational trial of drug-biologic bone graft for spinal fusion 50 patients have been enrolled in the Phase 2 trial Potential to addres...
Kuros Biosciences AG
About the publication
08 May 2023 05:18PM
Annual General Meeting of Kuros Biosciences approves all resolutions
CH0325814116
Schlieren (Zurich), Switzerland, May 8, 2023 – Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today. The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and the Consolidated Financial Statements for the year 2022 and took note of the Reports of t...
Kuros Biosciences AG
About the publication
08 May 2023 05:18PM
Annual General Meeting of Kuros Biosciences approves all resolutions
CH0325814116
Schlieren (Zurich), Switzerland, May 8, 2023 – Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today. The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and the Consolidated Financial Statements for the year 2022 and took note of the Reports of t...
Kuros Biosciences AG
About the publication
27 April 2023 07:00AM
Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023
CH0325814116
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Direct MagnetOs sales climbed from CHF 2.0 million in Q1 2022 to CHF 5.4 million in Q1 2023. Total medical device sales accelerate from 2.6 million to CHF 5.6 million Key data on efficacy of MagnetOs bone graft published in two prestigious, peer-reviewed scientific journals Kuros...
Kuros Biosciences AG
About the publication
27 April 2023 07:00AM
Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023
CH0325814116
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Direct MagnetOs sales climbed from CHF 2.0 million in Q1 2022 to CHF 5.4 million in Q1 2023. Total medical device sales accelerate from 2.6 million to CHF 5.6 million Key data on efficacy of MagnetOs bone graft published in two prestigious, peer-reviewed scientific journals Kuros...
Kuros Biosciences AG
About the publication
15 March 2023 07:00AM
Kuros Biosciences reports results for the full year 2022
CH0325814116
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Financial highlights Direct sales of MagnetOs rose 75% from CHF 6.9 million to CHF 12.1 million in 2022. Total revenue from medical devices CHF 13.3 million, up from CHF 8.3 million  Revenue from collaboration CHF 4.7 million vs CHF 5.5 million in 2021, due to licensing agreement...
Kuros Biosciences AG
About the publication
15 March 2023 07:00AM
Kuros Biosciences reports results for the full year 2022
CH0325814116
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Financial highlights Direct sales of MagnetOs rose 75% from CHF 6.9 million to CHF 12.1 million in 2022. Total revenue from medical devices CHF 13.3 million, up from CHF 8.3 million  Revenue from collaboration CHF 4.7 million vs CHF 5.5 million in 2021, due to licensing agreement...
Kuros Biosciences AG
About the publication
21 February 2023 07:00AM
Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft
CH0325814116
Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft 21.02.2023 / 07:00 CET/CEST Publications in peer reviewed Journal of Immunology and Regenerative Medicine and Clinical Oral Implants Research  Adds to body of evidence for MagnetOs,...
Kuros Biosciences AG
About the publication
21 February 2023 07:00AM
Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft
CH0325814116
Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft 21.02.2023 / 07:00 CET/CEST Publications in peer reviewed Journal of Immunology and Regenerative Medicine and Clinical Oral Implants Research  Adds to body of evidence for MagnetOs,...
Kuros Biosciences AG
About the publication
16 February 2023 06:01PM
Kuros Biosciences Announces Changes to Executive Management Team
CH0325814116
Ad hoc announcement pursuant to Article 53 of the SIX listing rules  New Chief Financial Officer (CFO) ad interim Schlieren (Zurich), Switzerland, 16 February 2023 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the appointment of Daniel Geiger as Chief Financial Officer (CFO) ad...
Kuros Biosciences AG
About the publication
16 February 2023 06:01PM
Kuros Biosciences Announces Changes to Executive Management Team
CH0325814116
Ad hoc announcement pursuant to Article 53 of the SIX listing rules  New Chief Financial Officer (CFO) ad interim Schlieren (Zurich), Switzerland, 16 February 2023 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the appointment of Daniel Geiger as Chief Financial Officer (CFO) ad...
Kuros Biosciences AG
About the publication
23 November 2022 07:00AM
Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH
CH0325814116
Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH 23.11.2022 / 07:00 CET/CEST First investigational trial of drug-biologic bone graft for spinal fusion No drug-related Serious Adverse Events (SAEs) reported in randomized stage of the trial...
Kuros Biosciences AG
About the publication
23 November 2022 07:00AM
Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH
CH0325814116
Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH 23.11.2022 / 07:00 CET/CEST First investigational trial of drug-biologic bone graft for spinal fusion No drug-related Serious Adverse Events (SAEs) reported in randomized stage of the trial...
Kuros Biosciences AG
About the publication
02 November 2022 07:00AM
Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules
CH0325814116
Kuros Biosciences AG / Key word(s): Study Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules 02.11.2022 / 07:00 CET/CEST Preliminary data shows 78% fusion rate vs 42% for autograft and 55-71% for other synthetic bone grafts  Level 1 clinical study compares MagnetOs Granules to local autograft in...
Kuros Biosciences AG
About the publication
02 November 2022 07:00AM
Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules
CH0325814116
Kuros Biosciences AG / Key word(s): Study Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules 02.11.2022 / 07:00 CET/CEST Preliminary data shows 78% fusion rate vs 42% for autograft and 55-71% for other synthetic bone grafts  Level 1 clinical study compares MagnetOs Granules to local autograft in...
Kuros Biosciences AG
About the publication
26 October 2022 07:00AM
Kuros reports 73% increase in MagnetOs sales in first nine months of 2022
CH0325814116
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Total product sales grow to CHF 8.9 million in the first nine months of 2022 Reaches major milestone of 10,000 patients treated with MagnetOs Positive first clinical data from planned randomized controlled trials Full commercial launch of MagnetOs Flex Matrix that recently recei...
Kuros Biosciences AG
About the publication
26 October 2022 07:00AM
Kuros reports 73% increase in MagnetOs sales in first nine months of 2022
CH0325814116
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Total product sales grow to CHF 8.9 million in the first nine months of 2022 Reaches major milestone of 10,000 patients treated with MagnetOs Positive first clinical data from planned randomized controlled trials Full commercial launch of MagnetOs Flex Matrix that recently recei...
Kuros Biosciences AG
About the publication
19 October 2022 07:00AM
Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week
CH0325814116
Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week 19.10.2022 / 07:00 CET/CEST MagnetOs Flex Matrix recognized as exemplary and innovative spine surgery product   Rounds out MagnetOs portfolio to provide more solutions for sur...
Kuros Biosciences AG
About the publication
19 October 2022 07:00AM
Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week
CH0325814116
Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week 19.10.2022 / 07:00 CET/CEST MagnetOs Flex Matrix recognized as exemplary and innovative spine surgery product   Rounds out MagnetOs portfolio to provide more solutions for sur...
Kuros Biosciences AG
About the publication
11 October 2022 07:00AM
Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting
CH0325814116
Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting 11.10.2022 / 07:00 CET/CEST First clinical data from five planned randomized controlled trials Show favorable fusion rate compared to autograft Launch of MagnetOs Flex Matrix expands p...
Kuros Biosciences AG
About the publication
11 October 2022 07:00AM
Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting
CH0325814116
Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting 11.10.2022 / 07:00 CET/CEST First clinical data from five planned randomized controlled trials Show favorable fusion rate compared to autograft Launch of MagnetOs Flex Matrix expands p...
Kuros Biosciences AG
About the publication
11 October 2022 07:00AM
Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting
CH0325814116
Kuros Biosciences AG / Key word(s): Conference Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting 11.10.2022 / 07:00 CET/CEST Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting   First clinical data from five planned randomized controlled trials...
Kuros Biosciences AG
About the publication
11 October 2022 07:00AM
Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting
CH0325814116
Kuros Biosciences AG / Key word(s): Conference Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting 11.10.2022 / 07:00 CET/CEST Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting   First clinical data from five planned randomized controlled trials...
Kuros Biosciences AG
About the publication
03 October 2022 07:00AM
Kuros Biosciences Appoints Chris Fair as Chief Operating Officer
CH0325814116
Ad hoc announcement pursuant to Article 53 of the SIX listing rules   Schlieren (Zurich), Switzerland, October 3, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has appointed Chris Fair as Chief Operating Officer (COO). Mr. Fair is a leader in the musculoskeletal an...
Kuros Biosciences AG
About the publication
03 October 2022 07:00AM
Kuros Biosciences Appoints Chris Fair as Chief Operating Officer
CH0325814116
Ad hoc announcement pursuant to Article 53 of the SIX listing rules   Schlieren (Zurich), Switzerland, October 3, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has appointed Chris Fair as Chief Operating Officer (COO). Mr. Fair is a leader in the musculoskeletal an...
Kuros Biosciences AG
About the publication
15 September 2022 07:00AM
Kuros Biosciences announces successful CHF 6.0 million private placement
CH0325814116
Schlieren (Zurich), Switzerland, September 15, 2022 – Kuros Biosciences AG (SIX:KURN) a leader in next generation bone graft technologies, announced today the successful completion of a CHF 6.0 million capital increase through a private placement of 3,750,000 new shares of Kuros with a par value of CHF 0.10 each (the "New Shares" and the "Placement...
Kuros Biosciences AG
About the publication
15 September 2022 07:00AM
Kuros Biosciences announces successful CHF 6.0 million private placement
CH0325814116
Schlieren (Zurich), Switzerland, September 15, 2022 – Kuros Biosciences AG (SIX:KURN) a leader in next generation bone graft technologies, announced today the successful completion of a CHF 6.0 million capital increase through a private placement of 3,750,000 new shares of Kuros with a par value of CHF 0.10 each (the "New Shares" and the "Placement...
Kuros Biosciences AG
About the publication
23 August 2022 07:00AM
Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key Milestones
CH0325814116
Kuros Biosciences AG / Key word(s): Corporate Action Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key Milestones 23.08.2022 / 07:00 CET/CEST Completion of enrolment in PARTNER clinical trial, comparing MagnetOs to autograft First patient treated with MagnetOs Flex Matrix 10,000 patients now treated with Ma...
Kuros Biosciences AG
About the publication
23 August 2022 07:00AM
Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key Milestones
CH0325814116
Kuros Biosciences AG / Key word(s): Corporate Action Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key Milestones 23.08.2022 / 07:00 CET/CEST Completion of enrolment in PARTNER clinical trial, comparing MagnetOs to autograft First patient treated with MagnetOs Flex Matrix 10,000 patients now treated with Ma...
Kuros Biosciences AG
About the publication
09 August 2022 05:50PM
Kuros Biosciences reports results for the first six months of 2022
CH0325814116
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules   Financial highlights CHF 29.4 million cash & cash equivalents, trade and other receivables as of June 30, 2022 Product sales increased by 58% to CHF 5.7 million   Operational highlights FDA cleared MagnetOs Granules for use in expanded spinal indications FDA cleared M...
Kuros Biosciences AG
About the publication
09 August 2022 05:50PM
Kuros Biosciences reports results for the first six months of 2022
CH0325814116
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules   Financial highlights CHF 29.4 million cash & cash equivalents, trade and other receivables as of June 30, 2022 Product sales increased by 58% to CHF 5.7 million   Operational highlights FDA cleared MagnetOs Granules for use in expanded spinal indications FDA cleared M...
Kuros Biosciences AG
About the publication
08 June 2022 07:00PM
Annual General Meeting of Kuros Biosciences approves all resolutions
CH0325814116
Schlieren (Zurich), Switzerland, June 8, 2022 – Kuros Biosciences (SIX:KURN) today announced that its Annual General Meeting approved all resolutions proposed by the Board of Directors.   Ad-hoc announcement pursuant to Article 53 of the SIX listing rules The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and...
Kuros Biosciences AG
About the publication
31 May 2022 07:00AM
Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial
CH0325814116
Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial 31.05.2022 / 07:00 Fusion rate 78%, vs 42% for autograft and 55-71% for other synthetic bone grafts First of five planned randomized...
Kuros Biosciences AG
About the publication
18 May 2022 07:00AM
Kuros Biosciences announces commercial launch of MagnetOs Easypack Putty in the U.S.
CH0325814116
Kuros Biosciences AG / Key word(s): Product Launch Kuros Biosciences announces commercial launch of MagnetOs Easypack Putty in the U.S. 18.05.2022 / 07:00 Soft, moldable formulation that is ready to use with no need for thawing or mixing Becomes third commercial MagnetOs product Schlieren (Zurich), Switzerland, May 18, 2022 ...
Kuros Biosciences AG
About the publication
27 April 2022 08:07AM
Kuros Biosciences continues strong commercial roll-out of MagnetOs bone graft
CH0325814116
Medical devices  Q1 2022 sales accelerate, rising 102% over Q1 2021 FDA cleared MagnetOs Granules for expanded indications in spine and MagnetOs Flex Matrix as bone void filler in posterolateral spine Promising first-in-human data from Phase II trial of Fibrin-PTH (KUR-113) in tibial fractures Milestone payment of $5 million to be received from ...
Kuros Biosciences AG
About the publication
21 April 2022 07:00AM
Kuros Biosciences's MagnetOs Flex Matrix Cleared by FDA for Spinal Indications
CH0325814116
Clearance as a bone void filler for use in the posterolateral spine Third FDA clearance for MagnetOs in the last 7 months Product provides opportunity to de-risk U.S. commercialization plans Schlieren (Zurich), Switzerland, April 21, 2022 - Kuros Biosciences ('Kuros' or the 'Company'), a leader in next generation bone graft technologies, announc...
Kuros Biosciences AG
About the publication
More Kuros Biosciences AG related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN